Company: HCWB
Filing Date: 2025-06-26
Form Type: 8-K
Source: 0000950170-25-090183
Chunk: 0

Company: HCW Biologics Inc.
Filing Date: 2025-06-26
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

Nasdaq Continued Listing Requirements

On June 26, 2025, HCW Biologics Inc. (the “ Company”) announced that it received formal notice from The Nasdaq Stock Market LLC (“ Nasdaq”) that the Company is in compliance with Listing Rule 5550(b)(1) (the “ Equity Rule”). On May 13, 2025, the Company received formal notice from Nasdaq that it regained compliance with the bid price requirement in Listing Rule 5550(a)(2), the public float requirement in Listing Rule 5550(a)(4), and the market value of publicly held shares requirement in Listing Rule 5550(a)(5). As a result, the Company is in compliance with all applicable criteria for continued listing on the Nasdaq Capital Market tier, and the previously disclosed listing compliance matters have been closed.

The Company was also notified that it will remain subject to a “ Panel Monitor,” as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the Nasdaq notice, through June 23, 2026. If, during the term of the Panel Monitor, the Company does not continue to remain in compliance with the Equity Rule, the Company will not be provided with the opportunity to submit a compliance plan for review by the Listing Qualifications Staff and must instead request a hearing before the Panel to address the deficiency, with such request staying any further action with respect to the Company’s listing on Nasdaq pending completion of the hearing process.